Parathyroid Changes After RAI in Patients With Differentiated Thyroid Carcinoma
ObjectiveThe purpose of this study was to investigate parathyroid hormone (PTH), serum calcium, phosphorus, and 25-hydroxyvitamin D (25-OH-VD) changes before and after radioactive iodine (RAI) in differentiated thyroid carcinoma (DTC) patients at different time points.MethodsA total of 259 DTC patie...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-05-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2021.671787/full |
id |
doaj-0f9e294ee296469dbd8e67a3330085d5 |
---|---|
record_format |
Article |
spelling |
doaj-0f9e294ee296469dbd8e67a3330085d52021-05-27T04:45:39ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922021-05-011210.3389/fendo.2021.671787671787Parathyroid Changes After RAI in Patients With Differentiated Thyroid CarcinomaLiu XiaoWenjie ZhangHongmei ZhuYueqi WangBin LiuRui HuangLin LiObjectiveThe purpose of this study was to investigate parathyroid hormone (PTH), serum calcium, phosphorus, and 25-hydroxyvitamin D (25-OH-VD) changes before and after radioactive iodine (RAI) in differentiated thyroid carcinoma (DTC) patients at different time points.MethodsA total of 259 DTC patients who received RAI were prospectively enrolled. We evaluated PTH, serum calcium, phosphorus, and 25-OH-VD levels at baseline pre-RAI, five days, six weeks, and six months post-RAI, respectively. We analyzed the risk factors of hypocalcemia at five days post-RAI.ResultsThe mean PTH, serum calcium and phosphorus values decreased five days post-RAI compared with pre-RAI (PTH 4.18 ± 1.23 pmol/L vs. 3.95 ± 1.41 pmol/L; calcium 2.27 ± 0.09 mmol/L vs. 2.20 ± 0.11 mmol/L; phosphorus 1.25 ± 0.17 vs. 0.98 ± 0.20 mmol/L, P < 0.05), and the differences were statistically significant. The mean 25-OH-VD levels did not significantly decrease at five days post-RAI. 21.2% (55/259) of patients had hypocalcemia at five days post-RAI, and all of them were given oral calcium supplements. At six weeks post-RAI, all of the above parameters were higher than those at five days post-RAI. Multivariate regression analysis showed that baseline pre-RAI serum calcium < 2.27 mmol/L, PTH < 4.18 pmol/L and negative 99mTcO4- thyroid imaging were risk factors for hypocalcemia at five days post-RAI.ConclusionFor DTC patients with normal PTH and serum calcium levels at pre-RAI, their PTH, serum calcium, and phosphorus levels decreased at five days post-RAI. About one-fifth of patients could have hypocalcemia at five days post-RAI. Lower baseline pre-RAI serum calcium and PTH levels and negative 99mTcO4- thyroid imaging were risk factors for hypocalcemia five days post-RAI.https://www.frontiersin.org/articles/10.3389/fendo.2021.671787/fulldifferentiated thyroid carcinomaparathyroid hormoneserum calciumserum phosphorusradioactive iodine |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Liu Xiao Wenjie Zhang Hongmei Zhu Yueqi Wang Bin Liu Rui Huang Lin Li |
spellingShingle |
Liu Xiao Wenjie Zhang Hongmei Zhu Yueqi Wang Bin Liu Rui Huang Lin Li Parathyroid Changes After RAI in Patients With Differentiated Thyroid Carcinoma Frontiers in Endocrinology differentiated thyroid carcinoma parathyroid hormone serum calcium serum phosphorus radioactive iodine |
author_facet |
Liu Xiao Wenjie Zhang Hongmei Zhu Yueqi Wang Bin Liu Rui Huang Lin Li |
author_sort |
Liu Xiao |
title |
Parathyroid Changes After RAI in Patients With Differentiated Thyroid Carcinoma |
title_short |
Parathyroid Changes After RAI in Patients With Differentiated Thyroid Carcinoma |
title_full |
Parathyroid Changes After RAI in Patients With Differentiated Thyroid Carcinoma |
title_fullStr |
Parathyroid Changes After RAI in Patients With Differentiated Thyroid Carcinoma |
title_full_unstemmed |
Parathyroid Changes After RAI in Patients With Differentiated Thyroid Carcinoma |
title_sort |
parathyroid changes after rai in patients with differentiated thyroid carcinoma |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Endocrinology |
issn |
1664-2392 |
publishDate |
2021-05-01 |
description |
ObjectiveThe purpose of this study was to investigate parathyroid hormone (PTH), serum calcium, phosphorus, and 25-hydroxyvitamin D (25-OH-VD) changes before and after radioactive iodine (RAI) in differentiated thyroid carcinoma (DTC) patients at different time points.MethodsA total of 259 DTC patients who received RAI were prospectively enrolled. We evaluated PTH, serum calcium, phosphorus, and 25-OH-VD levels at baseline pre-RAI, five days, six weeks, and six months post-RAI, respectively. We analyzed the risk factors of hypocalcemia at five days post-RAI.ResultsThe mean PTH, serum calcium and phosphorus values decreased five days post-RAI compared with pre-RAI (PTH 4.18 ± 1.23 pmol/L vs. 3.95 ± 1.41 pmol/L; calcium 2.27 ± 0.09 mmol/L vs. 2.20 ± 0.11 mmol/L; phosphorus 1.25 ± 0.17 vs. 0.98 ± 0.20 mmol/L, P < 0.05), and the differences were statistically significant. The mean 25-OH-VD levels did not significantly decrease at five days post-RAI. 21.2% (55/259) of patients had hypocalcemia at five days post-RAI, and all of them were given oral calcium supplements. At six weeks post-RAI, all of the above parameters were higher than those at five days post-RAI. Multivariate regression analysis showed that baseline pre-RAI serum calcium < 2.27 mmol/L, PTH < 4.18 pmol/L and negative 99mTcO4- thyroid imaging were risk factors for hypocalcemia at five days post-RAI.ConclusionFor DTC patients with normal PTH and serum calcium levels at pre-RAI, their PTH, serum calcium, and phosphorus levels decreased at five days post-RAI. About one-fifth of patients could have hypocalcemia at five days post-RAI. Lower baseline pre-RAI serum calcium and PTH levels and negative 99mTcO4- thyroid imaging were risk factors for hypocalcemia five days post-RAI. |
topic |
differentiated thyroid carcinoma parathyroid hormone serum calcium serum phosphorus radioactive iodine |
url |
https://www.frontiersin.org/articles/10.3389/fendo.2021.671787/full |
work_keys_str_mv |
AT liuxiao parathyroidchangesafterraiinpatientswithdifferentiatedthyroidcarcinoma AT wenjiezhang parathyroidchangesafterraiinpatientswithdifferentiatedthyroidcarcinoma AT hongmeizhu parathyroidchangesafterraiinpatientswithdifferentiatedthyroidcarcinoma AT yueqiwang parathyroidchangesafterraiinpatientswithdifferentiatedthyroidcarcinoma AT binliu parathyroidchangesafterraiinpatientswithdifferentiatedthyroidcarcinoma AT ruihuang parathyroidchangesafterraiinpatientswithdifferentiatedthyroidcarcinoma AT linli parathyroidchangesafterraiinpatientswithdifferentiatedthyroidcarcinoma |
_version_ |
1721425946324500480 |